Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
The General Hospital of Western Theater Command
45 participants
Jan 13, 2026
INTERVENTIONAL
Conditions
Summary
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Eligibility
Inclusion Criteria7
- Participants must meet the following criteria:
- The patient signed an informed consent form and voluntarily participated in the study.
- Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;
- Age ≥18 years, regardless of gender
- ECOG score 0-2
- Expected survival ≥3 months
- No severe impairment of function of major organs
Exclusion Criteria3
- If any of the following criteria are met, the participants must be excluded from this research project:
- \) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07483385